X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
index medicus (46) 46
female (32) 32
male (31) 31
middle aged (27) 27
aged (25) 25
oncology (23) 23
respiratory system (18) 18
adult (16) 16
animals (14) 14
lung neoplasms - drug therapy (13) 13
carcinoma, non-small-cell lung - drug therapy (12) 12
research (12) 12
chemotherapy (11) 11
treatment outcome (11) 11
aged, 80 and over (9) 9
cancer (9) 9
care and treatment (9) 9
geosciences, multidisciplinary (9) 9
non-small cell lung cancer (9) 9
analysis (8) 8
belgium (8) 8
carcinoma, non-small-cell lung - pathology (8) 8
geography, physical (8) 8
lung cancer, non-small cell (8) 8
lung neoplasms - pathology (8) 8
prospective studies (8) 8
cardiac & cardiovascular systems (7) 7
health aspects (7) 7
prognosis (7) 7
therapy (7) 7
archaeology (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
cell lung-cancer (6) 6
follow-up studies (6) 6
human medicine (6) 6
lung cancer (6) 6
lung neoplasms - genetics (6) 6
neoplasm staging (6) 6
tomography, x-ray computed (6) 6
trial (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
drug therapy (5) 5
evolutionary biology (5) 5
gefitinib (5) 5
genetics (5) 5
hematology, oncology and palliative medicine (5) 5
lung neoplasms - mortality (5) 5
medicine & public health (5) 5
mesothelioma (5) 5
multidisciplinary sciences (5) 5
paleontology (5) 5
pharmacology & pharmacy (5) 5
previously treated patients (5) 5
risk factors (5) 5
abridged index medicus (4) 4
acquired-resistance (4) 4
article (4) 4
biomarkers, tumor - blood (4) 4
cancer research (4) 4
cisplatin (4) 4
cohort studies (4) 4
diagnosis (4) 4
double-blind (4) 4
genetic aspects (4) 4
health care sciences & services (4) 4
inhibitor (4) 4
malignant pleural mesothelioma (4) 4
mesothelioma - blood (4) 4
nsclc (4) 4
open-label (4) 4
phylogeny (4) 4
pleural neoplasms - blood (4) 4
population (4) 4
pulmonary/respiratory (4) 4
rats (4) 4
research article (4) 4
retrospective studies (4) 4
substance p (4) 4
survival analysis (4) 4
time factors (4) 4
usage (4) 4
adolescent (3) 3
ancient dna (3) 3
anthropology (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
bevacizumab (3) 3
biology and life sciences (3) 3
cancer patients (3) 3
cancer therapies (3) 3
capsaicin (3) 3
carcinoma, non-small-cell lung - therapy (3) 3
care (3) 3
combined modality therapy (3) 3
computed tomography (3) 3
crizotinib (3) 3
decision making (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 619 - 626
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 03/2017, Volume 7, Issue 1, p. 44585
Journal Article
International Journal of COPD, ISSN 1176-9106, 03/2017, Volume 12, pp. 793 - 801
Background: Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy (2015) provides guidance for the treatment of chronic obstructive... 
Therapy | Chronic obstructive pulmonary disease | Inhaled corticosteroids | Long acting beta agonist | Long acting muscarinic antagonist | Guidelines | INDACATEROL | therapy | PREVENTION | QVA149 | SALMETEROL-FLUTICASONE | long acting muscarinic antagonist | OBSTRUCTIVE PULMONARY-DISEASE | REAL-LIFE | RESPIRATORY SYSTEM | long acting beta agonist | EXACERBATIONS | guidelines | TIOTROPIUM | chronic obstructive pulmonary disease | inhaled corticosteroids | Predictive Value of Tests | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - physiopathology | Patient Selection | Forced Expiratory Volume | Delphi Technique | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Evidence-Based Medicine | Consensus | Disease Progression | Adrenal Cortex Hormones - adverse effects | Muscarinic Antagonists - administration & dosage | Belgium | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Muscarinic antagonists | Complications and side effects | Lung diseases, Obstructive | Dosage and administration | Research | Drug therapy | inhalation therapy | delphi | COPD
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2014, Volume 87, Issue 2, pp. 89 - 95
Highlights • Crizotinib is a standard of care for ALK-positive lung cancer. • Crizotinib-associated AEs are mostly mild to moderate in severity. • Appropriate... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Crizotinib | Therapy management | Anaplastic lymphoma kinase (ALK) inhibitor | Treatment beyond progression | Non-small cell lung cancer (NSCLC) | Safety profile | OLIGOPROGRESSIVE DISEASE | KINASE | ACQUIRED-RESISTANCE | ANAPLASTIC LYMPHOMA | DISCONTINUATION | CANCER-PATIENTS | ONCOLOGY | RESPIRATORY SYSTEM | C-MET | INHIBITOR | TESTOSTERONE LEVELS | PROGRESSION | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Translocation, Genetic | Pyrazoles - therapeutic use | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Clinical Trials as Topic | Protein Kinase Inhibitors - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Disease Management | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Drug-Related Side Effects and Adverse Reactions - therapy | Pyrazoles - adverse effects | Pyridines - therapeutic use | Development and progression | Respiratory tract diseases | Care and treatment | Lung cancer, Non-small cell
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2011, Volume 6, Issue 11, pp. 1930 - 1937
Journal Article
Frontiers in Neuroscience, ISSN 1662-453X, 2019, Volume 13
Journal Article
Journal Article